U Beuers1, M H Nathanson, J L Boyer. 1. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Tauroursodeoxycholic acid (TUDCA) is of potential benefit in cholestatic disorders. However, the effects of TUDCA on cytosolic free calcium [(Ca2+)i], which regulates hepatocyte secretion, are unknown. METHODS: The effect of TUDCA on (Ca2+)i was investigated in groups of isolated rat hepatocytes by microspectrofluorometry and in single cells by confocal line scanning microscopy. RESULTS: Administration of TUDCA (5-50 mumol/L) induced a nearly fourfold increase of basal levels of (Ca2+)i. After a 15 minute treatment period, the TUDCA (10 mumol/L)-induced change in (Ca2+)i was higher than that of other mono-, di-, and trihydroxy bile acids at equimolar concentrations. Pretreatment with TUDCA (10 mumol/L) markedly reduced or abolished increases in (Ca2+)i induced by phenylephrine (1 mumol/L), the microsomal Ca(2+)-translocase inhibitor 2,5-di-(tert-butyl)-1,4-benzohydroquinone (25 mumol/L), or taurolithocholic acid (10-25 mumol/L). In Ca(2+)-free medium, TUDCA caused only a reduced and transient increase in (Ca2+)i. TUDCA (10 mumol/L) induced Ca2+ oscillations in all single cells that responded. However, levels of inositol-1,4,5-trisphosphate (IP3) in hepatocytes were not increased by treatment with TUDCA (10 mumol/L). CONCLUSIONS: TUDCA at physiological concentrations potently modulates (Ca2+)i signals in hepatocytes by (1) mobilizing microsomal IP3-sensitive Ca2+ stores by an IP3-independent mechanism, (2) initiating Ca2+ oscillations, and (3) inducing influx of extracellular Ca2+.
BACKGROUND:Tauroursodeoxycholic acid (TUDCA) is of potential benefit in cholestatic disorders. However, the effects of TUDCA on cytosolic free calcium [(Ca2+)i], which regulates hepatocyte secretion, are unknown. METHODS: The effect of TUDCA on (Ca2+)i was investigated in groups of isolated rat hepatocytes by microspectrofluorometry and in single cells by confocal line scanning microscopy. RESULTS: Administration of TUDCA (5-50 mumol/L) induced a nearly fourfold increase of basal levels of (Ca2+)i. After a 15 minute treatment period, the TUDCA (10 mumol/L)-induced change in (Ca2+)i was higher than that of other mono-, di-, and trihydroxy bile acids at equimolar concentrations. Pretreatment with TUDCA (10 mumol/L) markedly reduced or abolished increases in (Ca2+)i induced by phenylephrine (1 mumol/L), the microsomal Ca(2+)-translocase inhibitor 2,5-di-(tert-butyl)-1,4-benzohydroquinone (25 mumol/L), or taurolithocholic acid (10-25 mumol/L). In Ca(2+)-free medium, TUDCA caused only a reduced and transient increase in (Ca2+)i. TUDCA (10 mumol/L) induced Ca2+ oscillations in all single cells that responded. However, levels of inositol-1,4,5-trisphosphate (IP3) in hepatocytes were not increased by treatment with TUDCA (10 mumol/L). CONCLUSIONS:TUDCA at physiological concentrations potently modulates (Ca2+)i signals in hepatocytes by (1) mobilizing microsomal IP3-sensitive Ca2+ stores by an IP3-independent mechanism, (2) initiating Ca2+ oscillations, and (3) inducing influx of extracellular Ca2+.
Authors: Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen Journal: World J Gastroenterol Date: 2005-01-07 Impact factor: 5.742
Authors: Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones Journal: Nat Rev Gastroenterol Hepatol Date: 2015-02-03 Impact factor: 46.802
Authors: Laura N Cruz; Mateus T Guerra; Emma Kruglov; Albert Mennone; Celia R S Garcia; Ju Chen; Michael H Nathanson Journal: Hepatology Date: 2010-07 Impact factor: 17.425